Upadacitinib treatment in patients with moderate to severe atopic dermatitis: A retrospective single-centre Australian review of 14 patients post phase 3 clinical trial

被引：2
|
作者：
Bennett, Michaela [1 ,3 ]
Sinclair, Rodney D. [1 ,2 ]
Eisman, Samantha [1 ]
机构：
[1] Sinclair Dermatol, Melbourne, Vic, Australia
[2] Univ Melbourne, Melbourne, Vic, Australia
[3] Level 3,2 Wellington Parade, East Melbourne 3002, Australia
来源：
AUSTRALASIAN JOURNAL OF DERMATOLOGY | 2023年 / 64卷 / 01期
关键词：
atopic dermatitis; JAK; 1; inhibitors; JAK inhibitor treatment; Upadacitinib;
D O I：
10.1111/ajd.13969
中图分类号：
R75 [皮肤病学与性病学];
学科分类号：
100206 ;
摘要：
Recent phase 2b and phase 3 clinical trials support the safety and efficacy of the selective Janus kinase (JAK)-1 inhibitor upadacitinib (UPA) in the treatment of moderate to severe atopic dermatitis (AD). However, to date, there is little experience with UPA therapy for AD in Australia. We report findings from a retrospective study to better understand the therapeutic response and side effects noted in a single-centre Australian cohort.
引用
收藏
页码：146 / 150
页数：5
相关论文
共 50 条
  • [21] Efficacy and Safety of Abrocitinib in Patients With Moderate-to-Severe Atopic Dermatitis A Randomized Clinical Trial
    Silverberg, Jonathan, I
    Simpson, Eric L.
    Thyssen, Jacob P.
    Gooderham, Melinda
    Chan, Gary
    Feeney, Claire
    Biswas, Pinaki
    Valdez, Hernan
    DiBonaventura, Marco
    Nduaka, Chudy
    Rojo, Ricardo
    JAMA DERMATOLOGY, 2020, 156 (08) : 863 - 873
  • [22] Efficacy and safety of upadacitinib through 140 weeks in adolescents and adults with moderate-to-severe atopic dermatitis: phase 3 randomized clinical trial results
    Silverberg, Jonathan, I
    Guttman-Yassky, Emma
    Simpson, Eric L.
    Papp, Kim A.
    Blauvelt, Andrew
    Chu, Chia-Yu
    Hong, H. Chih-ho
    Gold, Linda F. Stein
    Bieber, Thomas
    Kabashima, Kenji
    Rosmarin, David
    Gamelli, Amy
    Calimlim, Brian
    Vigna, Namita
    Hu, Xiaofei
    Yang, Yang
    Wu, Xiaoqiang
    Huang, Xiaohong
    Suravaram, Smitha
    Teixeira, Henrique D.
    Raymundo, Eliza
    Irvine, Alan D.
    BRITISH JOURNAL OF DERMATOLOGY, 2024, 190 : II8 - II8
  • [23] Real-life experience of upadacitinib for the treatment of adult patients with moderate-to-severe atopic dermatitis - a case series
    Feraru, G.
    Nevet, M. J.
    Samuelov, L.
    Hodak, E.
    Avitan-Hersh, E.
    Ziv, M.
    Dodiuk-Gad, R. P.
    JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY, 2022, 36 (10) : E832 - E833
  • [24] Clinical outcomes and management of JAK inhibitor-associated acne in patients with moderate-to-severe atopic dermatitis undergoing upadacitinib: A multicenter retrospective study
    Avallone, Gianluca
    Mastorino, Luca
    Tavoletti, Gianluca
    Macagno, Nicole
    Barei, Francesca
    Schena, Donatella
    Rossi, Mariateresa
    Magnaterra, Elisabetta
    Antonelli, Flaminia
    Babino, Graziella
    Viola, Riccardo
    Gargiulo, Luigi
    Conforti, Claudio
    Rapparini, Luca
    Errichetti, Enzo
    Patruno, Cataldo
    Ruggiero, Pasqualina
    Roccuzzo, Gabriele
    Maronese, Carlo A.
    Girolomoni, Giampiero
    Gola, Massimo
    Chiricozzi, Andrea
    Balato, Anna
    Ambrogio, Francesca
    Narcisi, Alessandra
    Zalaudek, Iris
    Gurioli, Carlotta
    Napolitano, Maddalena
    Marzano, Angelo, V
    Foti, Caterina
    Costanzo, Antonio
    Piraccini, Bianca M.
    Ferrucci, Silvia M.
    Ortoncelli, Michela
    Quaglino, Pietro
    Ribero, Simone
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2024, 90 (05) : 1031 - 1034
  • [25] Efficacy and safety of abrocitinib in Chinese patients with moderate-to-severe atopic dermatitis: A post hoc analysis of the JADE REGIMEN phase 3 trial
    Li, Hang
    Cheng, Hao
    Lu, Qianjin
    Lai, Wei
    Tao, Xiaohua
    Encinas, Gerardo A.
    Vyas, Shefali
    Wang, Bo
    Luo, Xin
    Li, Shiqi
    CHINESE MEDICAL JOURNAL, 2024, 137 (16) : 1991 - 1992
  • [26] Efficacy and safety of abrocitinib in Chinese patients with moderate-to-severe atopic dermatitis: A post hoc analysis of the JADE REGIMEN phase 3 trial
    Li Hang
    Cheng Hao
    Lu Qianjin
    Lai Wei
    Tao Xiaohua
    Encinas Gerardo A
    Vyas Shefali
    Wang Bo
    Luo Xin
    Li Shiqi
    中华医学杂志英文版, 2024, 137 (16)
  • [27] Discontinuation of topical corticosteroids in upadacitinib-treated patients with moderate-to-severe atopic dermatitis: analysis from the AD Up phase III trial
    Reich, K.
    Boguniewicz, M.
    Kabashima, K.
    Barbarot, S.
    Girolomoni, G.
    Mendes-Bastos, P.
    Gamelli, A.
    Liu, Y.
    Teixeira, H.
    Armstrong, A.
    BRITISH JOURNAL OF DERMATOLOGY, 2021, 185 (03) : E118 - E118
  • [28] Management of atopic dermatitis in patients non-responsive to dupilumab: A single-centre retrospective-cohort study
    Greenzaid, Jonathan D.
    Hrin, Matthew L.
    Feldman, Steven R.
    Strowd, Lindsay C.
    JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY, 2024, 38 (11) : e1010 - e1012
  • [29] Effectiveness of Switching From Upadacitinib to Tralokinumab in Patients With Moderate-to-Severe Atopic Dermatitis: A Real-World Clinical Practice
    Hagino, Teppei
    Saeki, Hidehisa
    Fujimoto, Eita
    Kanda, Naoko
    ANNALS OF DERMATOLOGY, 2025, 37 (02) : 86 - 95
  • [30] Observational 24-week study to assess clinical response to upadacitinib posttrial in patients with moderate-to-severe atopic dermatitis
    Batalla, Ana
    Suh-Oh, Hae Jin
    Hernandez, Gregorio Carretero
    Miquel-Miquel, Javier
    Botella-Estrada, Rafael
    Martorell-Calatayud, Antonio
    Sanz-Motilva, Virginia
    Figueras-Nart, Ignasi
    Florez, Angeles
    JEADV CLINICAL PRACTICE, 2023, 2 (03): : 571 - 575
12345